Market revenue in 2023 | USD 437.7 million |
Market revenue in 2030 | USD 745.5 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.63% in 2024. Horizon Databook has segmented the Canada in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s in vivo CRO market is anticipated to witness lucrative growth from 2022 to 2030. Growth in the country can be underpinned by the presence of a well-established healthcare system and increasing number of pharmaceutical & biotech companies, supported by both the public & private sectors.
Canada holds around 2.1% of the global pharmaceutical sales market, positioning it as the 9th largest market worldwide. This sector benefits from highly trained scientists, a well-educated workforce, business-friendly government policies, and high R&D operations.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account